[
  {
    "ts": null,
    "headline": "Revvity Inc. stock outperforms competitors on strong trading day",
    "summary": "Revvity Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b247fc0b858c144fa3e8e189fb7c3024d7ff80517cdc38f8d5f11d2a1fab7cf2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747675140,
      "headline": "Revvity Inc. stock outperforms competitors on strong trading day",
      "id": 134679938,
      "image": "",
      "related": "RVTY",
      "source": "MarketWatch",
      "summary": "Revvity Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b247fc0b858c144fa3e8e189fb7c3024d7ff80517cdc38f8d5f11d2a1fab7cf2"
    }
  },
  {
    "ts": null,
    "headline": "Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing",
    "summary": "WALTHAM, Mass., May 19, 2025--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings.",
    "url": "https://finnhub.io/api/news?id=8ebec96b484e76b9ab07d3278fca8cc5389e53e505e6494f8e21f3bd85199e6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747656000,
      "headline": "Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing",
      "id": 134577775,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass., May 19, 2025--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings.",
      "url": "https://finnhub.io/api/news?id=8ebec96b484e76b9ab07d3278fca8cc5389e53e505e6494f8e21f3bd85199e6f"
    }
  }
]